scholarly article | Q13442814 |
P50 | author | Jian Wu | Q82564702 |
P2093 | author name string | Yang Li | |
Junbo Ge | |||
Yunzeng Zou | |||
Shijun Wang | |||
Hui Gong | |||
Jie Yuan | |||
Yong Ye | |||
Guoliang Jiang | |||
Weijing Zhang | |||
Xingxu Wang | |||
Peipei Yin | |||
Zhiwen Ding | |||
Jingmin Zhou | |||
P2860 | cites work | Neuregulin1/ErbB4 signaling induces cardiomyocyte proliferation and repair of heart injury | Q28252995 |
2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines | Q29620107 | ||
Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma | Q29622918 | ||
Comparing angiotensin II receptor blockers on benefits beyond blood pressure | Q30360678 | ||
Modeling the effects of β1-adrenergic receptor blockers and polymorphisms on cardiac myocyte Ca2+ handling. | Q30371695 | ||
Autophagy in hypertensive heart disease | Q33726330 | ||
Autophagy and oxidative stress in cardiovascular diseases | Q34506174 | ||
ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the | Q34640762 | ||
The intracellular renin-angiotensin system in the heart | Q34960931 | ||
Mechanical stress triggers cardiomyocyte autophagy through angiotensin II type 1 receptor-mediated p38MAP kinase independently of angiotensin II. | Q35107771 | ||
Working outside the system: an update on the unconventional behavior of the renin-angiotensin system components | Q36099604 | ||
Induction of cardiac fibrosis by β-blocker in G protein-independent and G protein-coupled receptor kinase 5/β-arrestin2-dependent Signaling pathways. | Q36318886 | ||
Stop and go: anti-proliferative and mitogenic functions of the transcription factor C/EBPbeta | Q36474712 | ||
Novel and potential future biomarkers for assessment of the severity and prognosis of chronic heart failure : a clinical review | Q36666482 | ||
ErbB receptors, their ligands, and the consequences of their activation and inhibition in the myocardium | Q37145440 | ||
The electrophysiological effects of qiliqiangxin on cardiac ventricular myocytes of rats | Q37286000 | ||
Apoptosis in pressure overload-induced heart hypertrophy in the rat. | Q37356640 | ||
Role of angiotensin-converting enzyme inhibitors in vascular modulation: beyond the hypertensive effects | Q37678849 | ||
Direct renin inhibitors as antihypertensive agents. | Q37755936 | ||
The diagnosis and management of chronic heart failure: review following the publication of the NICE guidelines. | Q37836177 | ||
The role of cell signalling in the crosstalk between autophagy and apoptosis | Q38168965 | ||
The regulation of β-adrenergic receptor-mediated PKA activation by substrate stiffness via microtubule dynamics in human MSCs | Q38980205 | ||
Anti-beta1-adrenergic receptor autoantibodies are potent stimulators of the ERK1/2 pathway in cardiac cells | Q40107520 | ||
Medical therapy can improve the biological properties of the chronically failing heart. A new era in the treatment of heart failure | Q41196451 | ||
Essential role for UVRAG in autophagy and maintenance of cardiac function. | Q41924071 | ||
Myocyte apoptosis occurs early during the development of pressure-overload hypertrophy in infant myocardium | Q42194690 | ||
C/EBPβ controls exercise-induced cardiac growth and protects against pathological cardiac remodeling | Q42591580 | ||
Comparison of angiotensin II type 1-receptor blockers to regress pressure overload-induced cardiac hypertrophy in mice | Q42859674 | ||
Mechanical stress-evoked but angiotensin II-independent activation of angiotensin II type 1 receptor induces cardiac hypertrophy through calcineurin pathway. | Q43004529 | ||
Triple-combination treatment with olmesartan medoxomil/amlodipine/ hydrochlorothiazide in Hispanic/Latino patients with hypertension: the TRINITY study | Q43810164 | ||
Qiliqiangxin regulates the balance between tumor necrosis factor-alpha and interleukin-10 and improves cardiac function in rats with myocardial infarction | Q44478235 | ||
Convergence in findings from randomized trials and elaborately analysed observational data on mortality reduction with carvedilol in heart failure in comparison with metoprolol | Q44581731 | ||
Qiliqiangxin improves cardiac function in spontaneously hypertensive rats through the inhibition of cardiac chymase | Q44643319 | ||
The large-scale placebo-controlled beta-blocker studies in systolic heart failure revisited: results from CIBIS-II, COPERNICUS and SENIORS-SHF compared with stratified subsets from MERIT-HF. | Q44694136 | ||
Mechanical stress activates angiotensin II type 1 receptor without the involvement of angiotensin II. | Q44898088 | ||
Effects of angiotensin-converting enzyme inhibitor, captopril, on bone of mice with streptozotocin-induced type 1 diabetes. | Q45859011 | ||
Ryanodine receptor type 2 is required for the development of pressure overload-induced cardiac hypertrophy. | Q46010252 | ||
Life and death partners: apoptosis, autophagy and the cross-talk between them | Q46072576 | ||
Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. | Q46426098 | ||
A multicenter, randomized, double-blind, parallel-group, placebo-controlled study of the effects of qili qiangxin capsules in patients with chronic heart failure | Q48228910 | ||
Comparison of alprazolam versus captopril in high blood pressure: a randomized controlled trial. | Q50645690 | ||
Qiliqiangxin inhibits the development of cardiac hypertrophy, remodeling, and dysfunction during 4 weeks of pressure overload in mice. | Q54550660 | ||
Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)–Added trial | Q57396324 | ||
p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload | Q57396501 | ||
[Guidelines for the diagnosis and management of chronic heart failure] | Q80874938 | ||
Promising small molecule for heart failure targeting adrenal catecholamine release and β-adrenergic receptor signaling in the heart | Q87618243 | ||
Chronic treatment with qiliqiangxin ameliorates aortic endothelial cell dysfunction in diabetic rats | Q88034124 | ||
P433 | issue | 6 | |
P407 | language of work or name | English | Q1860 |
P304 | page(s) | 628-639 | |
P577 | publication date | 2015-06-01 | |
P1433 | published in | Journal of Cardiovascular Pharmacology | Q2125808 |
P1476 | title | Combination Treatment With Antihypertensive Agents Enhances the Effect of Qiliqiangxin on Chronic Pressure Overload-induced Cardiac Hypertrophy and Remodeling in Male Mice | |
P478 | volume | 65 |
Q33834911 | Effects of Baicalin on Blood Pressure and Left Ventricular Remodeling in Rats with Renovascular Hypertension |
Q90750222 | Potential Therapeutic Application of Estrogen in Gender Disparity of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis |
Q33717198 | Traditional Chinese Medication Qiliqiangxin Protects Against Cardiac Remodeling and Dysfunction in Spontaneously Hypertensive Rats |